Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab retreatment with panobinostat, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
2020-000382-16Phase 2Terminated
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, panobinostat, bortezomib and dexamethasone in multiple myeloma (MM), sponsored by Universitätsklinikum Freiburg. Primary endpoint: Response to Dara-PanVD. Started Nov 2020; status: terminated.
02
Drugs
daratumumabpanobinostatbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2020-000382-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000382-16.